{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:43:14Z","timestamp":1761100994766},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2009,8,24]],"date-time":"2009-08-24T00:00:00Z","timestamp":1251072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2009,8,24]],"date-time":"2009-08-24T00:00:00Z","timestamp":1251072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1038\/bmt.2009.214","type":"journal-article","created":{"date-parts":[[2009,8,24]],"date-time":"2009-08-24T10:44:46Z","timestamp":1251110686000},"page":"559-569","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Second hematopoietic SCT for lymphoma patients who relapse after autotransplantation: another autograft or switch to allograft?"],"prefix":"10.1038","volume":"44","author":[{"given":"C O","family":"Freytes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H M","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,8,24]]},"reference":[{"key":"BFbmt2009214_CR1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/sj.bmt.1702796","volume":"27","author":"HM Lazarus","year":"2001","unstructured":"Lazarus HM, Loberiza Jr FR, Zhang MJ, Armitage JO, Ballen KK, Bashey A et al. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant 2001; 27: 387\u2013396.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2009214_CR2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.bbmt.2003.09.015","volume":"10","author":"JM Vose","year":"2004","unstructured":"Vose JM, Rizzo DJ, Tao-Wu J, Armitage JO, Bashey A, Burns LJ et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in first relapse or second remission. Biol Blood Marrow Transplant 2004; 10: 116\u2013127.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2009214_CR3","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMra052638","volume":"354","author":"EA Copelan","year":"2006","unstructured":"Copelan EA . Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813\u20131826.","journal-title":"N Engl J Med"},{"key":"BFbmt2009214_CR4","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/CCO.0b013e32830b61ac","volume":"20","author":"PM Barr","year":"2008","unstructured":"Barr PM, Lazarus HM . Follicular non-Hodgkin's lymphoma: long-term results of stem-cell transplantation. Curr Opin Oncol 2008; 20: 502\u2013508.","journal-title":"Curr Opin Oncol"},{"key":"BFbmt2009214_CR5","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","volume":"21","author":"HC Schouten","year":"2003","unstructured":"Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnson HE et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918\u20133927.","journal-title":"J Clin Oncol"},{"key":"BFbmt2009214_CR6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.blre.2006.01.001","volume":"20","author":"K Van Besien","year":"2006","unstructured":"Van Besien K . The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma. Blood Rev 2006; 20: 235\u2013244.","journal-title":"Blood Rev"},{"key":"BFbmt2009214_CR7","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/sj.bmt.1703888","volume":"31","author":"O Paltiel","year":"2003","unstructured":"Paltiel O, Rubinstein C, Or R, Nagler A, Gordon L, Deutsch L et al. Factors associated with survival in patients with progressive disease following autologous stem cell transplantation for lymphoma. Bone Marrow Transplant 2003; 31: 565\u2013569.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2009214_CR8","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/sj.bmt.1704214","volume":"32","author":"T Kewalramani","year":"2003","unstructured":"Kewalramani T, Nimer SD, Zelenetz AD, Malhotra S, Qin J, Yahalom J et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2003; 32: 673\u2013679.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2009214_CR9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1600-0609.2005.00481.x","volume":"75","author":"T Kuittinen","year":"2005","unstructured":"Kuittinen T, Wiklund T, Remes K, Elonen E, Lehtinen T, Kuittinen O et al. Outcome of progressive disease after autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: a nation-wide survey. Eur J Haematol 2005; 75: 199\u2013205.","journal-title":"Eur J Haematol"},{"key":"BFbmt2009214_CR10","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825\u20132833.","journal-title":"J Clin Oncol"},{"key":"BFbmt2009214_CR11","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/sj.bmt.1701944","volume":"24","author":"D Tsai","year":"1999","unstructured":"Tsai D, Moore H, Hardy C, Porter D, Loh E, Vaughn D et al. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation. Bone Marrow Transplant 1999; 24: 521\u2013526.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2009214_CR12","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/00130404-200209000-00007","volume":"8","author":"D Pan","year":"2002","unstructured":"Pan D, Moskowitz CH, Zelenetz AD, Straus D, Kewalaramani T, Noy A et al. Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation. Cancer J 2002; 8: 371\u2013376.","journal-title":"Cancer J"},{"key":"BFbmt2009214_CR13","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1053\/bbmt.2002.v8.pm12434949","volume":"8","author":"H Kaya","year":"2002","unstructured":"Kaya H, Keung YK, Case D, Cruz JM, Perry JJ, Radford JE et al. Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2002; 8: 544\u2013549.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2009214_CR14","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1080\/10428190601158639","volume":"48","author":"JM Vose","year":"2007","unstructured":"Vose JM, Bierman PJ, Loberiza Jr FR, Bociek RG, Matso D, Armitage JO . Phase I trial of (90) Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation. Leuk Lymphoma 2007; 48: 683\u2013690.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt2009214_CR15","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.V80.8.2142.2142","volume":"80","author":"JM Vose","year":"1992","unstructured":"Vose JM, Bierman PJ, Anderson JR, Kessinger A, Pierson J, Nelson J et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 1992; 80: 2142\u20132148.","journal-title":"Blood"},{"key":"BFbmt2009214_CR16","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1200\/JCO.1998.16.2.584","volume":"16","author":"R Little","year":"1998","unstructured":"Little R, Wittes RE, Longo DL, Wilson WH . Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant. J Clin Oncol 1998; 16: 584\u2013588.","journal-title":"J Clin Oncol"},{"key":"BFbmt2009214_CR17","first-page":"517","volume":"6","author":"AF Cashen","year":"2008","unstructured":"Cashen AF, Bartlett NL . Salvage regimens for Hodgkin's lymphoma. Clin Adv Hematol Oncol 2008; 6: 517\u2013524.","journal-title":"Clin Adv Hematol Oncol"},{"key":"BFbmt2009214_CR18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V112.11.3.3","volume":"112","author":"JW Friedberg","year":"2008","unstructured":"Friedberg JW, Sharman J, Schaefer-Cutillo J, Johnston PB, De Vos S, LaCasce A et al. Fostamatinib disodium (FosD) of Syk, is well tolerated and has significant clinical activity in diffuse large cell B-cell lymphoma (DLCBL) and chronic lymphocytic leukemia (SLL\/CLL). Blood 2008; 112: 3\u20134 (abstract 3).","journal-title":"Blood"},{"key":"BFbmt2009214_CR19","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.exphem.2008.04.018","volume":"36","author":"J Castillo","year":"2008","unstructured":"Castillo J, Winer E, Quesenberry P . Newer monoclonal antibodies for hematological malignancies. Exp Hematol 2008; 36: 755\u2013768.","journal-title":"Exp Hematol"},{"key":"BFbmt2009214_CR20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1182\/blood.V112.11.262.262","volume":"112","author":"PL Zinzani","year":"2008","unstructured":"Zinzani PL, Witzig TE, Vose JM, Reeder CB, Buckstein R, Haioun C et al. Confirmation of the efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory lymphoma: results of an international study (NHL-003). Blood 2008; 112: 103 (abstract 262).","journal-title":"Blood"},{"key":"BFbmt2009214_CR21","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1182\/blood.V112.11.369.369","volume":"112","author":"JW Friedberg","year":"2008","unstructured":"Friedberg JW, Younes A, Fisher DC, Gordon LI, Moore JO, Czuzman MS et al. Durable responses in patients treated with galiximab (anti-CD80) in combination with rituximab for relapsed or refractory follicular lymphoma: long-term follow-up of a phase II clinical trial. Blood 2008; 112: 369\u2013370 (abstract 1004).","journal-title":"Blood"},{"key":"BFbmt2009214_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1365-2141.2008.07466.x","volume":"145","author":"O O\u2019Connor","year":"2009","unstructured":"O\u2019Connor O, Moskowitz C, Portlock C, Hamlin P, Straus D, Dumitrescu O et al. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase II clinical trial. Br J Haematol 2009l; 145: 34\u201339.","journal-title":"Br J Haematol"},{"key":"BFbmt2009214_CR23","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","volume":"26","author":"JW Friedberg","year":"2008","unstructured":"Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single agent study. J Clin Oncol 2008; 26: 204\u2013210. Erratum in: J Clin Oncol 2008; 26: 1911.","journal-title":"J Clin Oncol"},{"key":"BFbmt2009214_CR24","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1093\/annonc\/mdn031","volume":"19","author":"M Crump","year":"2008","unstructured":"Crump M, Coiffier B, Jacobsen ED, Sun L, Ricker JL, Xie H et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 2008; 19: 964\u2013969.","journal-title":"Ann Oncol"},{"key":"BFbmt2009214_CR25","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3747\/co.v16i2.428","volume":"16","author":"MA Dickson","year":"2009","unstructured":"Dickson MA, Schwartz GK . Development of cell-cycle inhibitors for cancer therapy. Curr Oncol 2009; 16: 36\u201343.","journal-title":"Curr Oncol"},{"key":"BFbmt2009214_CR26","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/j.1365-2141.2009.07657.x","volume":"145","author":"DT Teachey","year":"2009","unstructured":"Teachey DT, Grupp SA, Brown VI . Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol 2009; 145: 569\u2013580.","journal-title":"Br J Haematol"},{"key":"BFbmt2009214_CR27","doi-asserted-by":"publisher","first-page":"6161","DOI":"10.1182\/blood-2008-10-187138","volume":"113","author":"EA Rossi","year":"2009","unstructured":"Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH . Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20\/CD22 antibodies in lymphoma. Blood 2009; 113: 6161\u20136171.","journal-title":"Blood"},{"key":"BFbmt2009214_CR28","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1002\/cncr.23890","volume":"113","author":"JP Leonard","year":"2008","unstructured":"Leonard JP, Schuster SJ, Emmanoulides C, Couture F, Teoh N, Wegener WA et al. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin's lymphoma. Cancer 2008; 113: 2714\u20132723.","journal-title":"Cancer"},{"key":"BFbmt2009214_CR29","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.coph.2008.06.015","volume":"8","author":"T Taldone","year":"2008","unstructured":"Taldone T, Gozman A, Maharaj R, Chiosis G . Targeting Hsp90: small molecule inhibitors and their clinical development. Curr Opin Pharmacol 2008; 8: 370\u2013374.","journal-title":"Curr Opin Pharmacol"},{"key":"BFbmt2009214_CR30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/blood.V112.11.266.266","volume":"112","author":"L Fayad","year":"2008","unstructured":"Fayad L, Patel H, Verhoef G, Smith MR, Johnson PWM, Czuzman MS et al. Safety and clinical activity of the anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) in combination with rituximab in follicular lymphoma or diffuse large B-cell lymphoma: preliminary report of a phase 1\/2 study. Blood 2008; 112: 105 (abstract 1004).","journal-title":"Blood"},{"key":"BFbmt2009214_CR31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/sj.bmt.1700614","volume":"19","author":"M de Lima","year":"1997","unstructured":"de Lima M, van Besien KW, Giralt SA, Khouri IF, Mehra R, Andersson BS et al. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant 1997; 19: 121\u2013127.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2009214_CR32","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/sj.bmt.1703546","volume":"29","author":"TS Lin","year":"2002","unstructured":"Lin TS, Avalos BR, Penza SL, Marcucci G, Elder PJ, Copelan EA . Second autologous stem cell transplant for multiply relapsed Hodgkin's disease. Bone Marrow Transplant 2002; 29: 763\u2013767.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2009214_CR33","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/sj.thj.6200545","volume":"5","author":"C Lenain","year":"2004","unstructured":"Lenain C, Dumontet C, Gargi T, Chassagne C, Berger F, Perol D et al. Second autologous transplantation after failure of a first autologous transplant in 18 patients with non-Hodgkin's lymphoma. Hematol J 2004; 5: 403\u2013409.","journal-title":"Hematol J"},{"key":"BFbmt2009214_CR34","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1200\/JCO.1997.15.4.1595","volume":"15","author":"E Vandenberghe","year":"1997","unstructured":"Vandenberghe E, Pearce R, Taghipour G, Fouillard L, Goldstone AH . Role of a second transplant in the management of poor-prognosis lymphomas: a report from the European Blood and Bone Marrow Registry. J Clin Oncol 1997; 15: 1595\u20131600.","journal-title":"J Clin Oncol"},{"key":"BFbmt2009214_CR35","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.bbmt.2008.05.021","volume":"14","author":"SM Smith","year":"2008","unstructured":"Smith SM, van Besien K, Carreras J, Bashey A, Cairo MS, Freytes CO et al. Second Autologous Hematopoietic Stem Cell Transplant (HCT) for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant 2008; 14: 904\u2013912.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2009214_CR36","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/sj.bmt.1704484","volume":"33","author":"M Streetly","year":"2004","unstructured":"Streetly M, Kazmi M, Radia D, Hoyle C, Schey SA . Second autologous transplant with cyclosporin\/interferon alpha-induced graft versus host disease for patients who have failed first-line consolidation. Bone Marrow Transplant 2004; 33: 1131\u20131135.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2009214_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1083-8791(00)70047-4","volume":"6","author":"KG Blume","year":"2000","unstructured":"Blume KG, Thomas ED . A review of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2000; 6: 1\u201312.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2009214_CR38","first-page":"119","volume":"4","author":"HC Schouten","year":"1989","unstructured":"Schouten HC, Armitage JO, Klassen LW, Vaughan WP, Bierman PJ, Weisenburger D et al. Allogeneic bone marrow transplantation in patients with lymphoma relapsing after autologous marrow transplantation. Bone Marrow Transplant 1989; 4: 119\u2013121.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2009214_CR39","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/sj.bmt.1700989","volume":"20","author":"T Tsai","year":"1997","unstructured":"Tsai T, Goodman S, Saez R, Schiller G, Adkins D, Callander N et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplant 1997; 20: 859\u2013863.","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl 1","key":"BFbmt2009214_CR40","first-page":"321a","volume":"92","author":"P Bierman","year":"1998","unstructured":"Bierman P, Kottaridis J, Kollath J, Vose J, Linch D, Mckinnon S et al. Allogeneic transplantation following failure of autologous transplantation for lymphoma. Blood 1998; 92 (Suppl 1): 321a (abstract 1315).","journal-title":"Blood"},{"key":"BFbmt2009214_CR41","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/S1083-8791(00)70009-7","volume":"6","author":"JP Radich","year":"2000","unstructured":"Radich JP, Gooley T, Sanders JE, Anasetti C, Chauncey T, Appelbaum FR . Second allogeneic transplantation after failure of first autologous transplantation. Biol Blood Marrow Transplant 2000; 6: 272\u2013279.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2009214_CR42","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/sj.bmt.1702567","volume":"26","author":"C Martinez","year":"2000","unstructured":"Martinez C, Carreras E, Rovira M, Urbano-Ispizua A, Esteve J, Perales M et al. Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation. Bone Marrow Transplant 2000; 26: 677\u2013679.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2009214_CR43","first-page":"646","volume":"86","author":"C di Grazia","year":"19200","unstructured":"di Grazia C, Raiola AM, Van Lint MT, Lamparelli T, Gualandi F, Berisso G et al. Conventional hematopoietic stem cell transplants from identical or alternative donors are feasible in recipients relapsing after an autograft. Haematologica 200; 86: 646\u2013651.","journal-title":"Haematologica"},{"key":"BFbmt2009214_CR44","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/sj.bmt.1704233","volume":"32","author":"S Seropian","year":"2003","unstructured":"Seropian S, Bahceci E, Cooper DL . Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma. Bone Marrow Transplant 2003; 32: 763\u2013769.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2009214_CR45","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S1083-8791(03)70007-X","volume":"9","author":"JP Cooney","year":"2003","unstructured":"Cooney JP, Stiff PJ, Toor AA, Parthasarathy M . BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective. Biol Blood Marrow Transplant 2003; 9: 177\u2013182.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2009214_CR46","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1182\/blood-2004-01-0231","volume":"104","author":"CO Freytes","year":"2004","unstructured":"Freytes CO, Loberiza FR, Rizzo JD, Bashey A, Bredeson CN, Cairo MS et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood 2004; 104: 3797\u20133803.","journal-title":"Blood"},{"key":"BFbmt2009214_CR47","doi-asserted-by":"crossref","unstructured":"National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982; 49: 2112\u20132135.","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2"},{"key":"BFbmt2009214_CR48","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/S0301-472X(00)00511-7","volume":"28","author":"A Nagler","year":"2000","unstructured":"Nagler A, Or R, Naparstek E, Varadi G, Slavin S . Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation. Exp Hematol 2000; 28: 1096\u20131104.","journal-title":"Exp Hematol"},{"key":"BFbmt2009214_CR49","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1053\/bbmt.2001.v7.pm11760148","volume":"7","author":"BR Dey","year":"2001","unstructured":"Dey BR, McAfee S, Sackstein R, Colby C, Saidman S, Weymouth D et al. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 604\u2013612.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2009214_CR50","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/sj.bmt.1703134","volume":"28","author":"M Mohty","year":"2001","unstructured":"Mohty M, Fegueux N, Exbrayat C, Lu ZY, Legouffe E, Quittet P et al. Reduced intensity conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy. Bone Marrow Transplant 2001; 28: 335\u2013339.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2009214_CR51","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1053\/bbmt.2001.v7.pm11349810","volume":"7","author":"DL Porter","year":"2001","unstructured":"Porter DL, Luger SM, Duffy KM, Stadtmauer EA, Laport G, Schuster SJ et al. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 230\u2013238.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2009214_CR52","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1200\/JCO.2002.11.088","volume":"20","author":"K Branson","year":"2002","unstructured":"Branson K, Chopra R, Kottaridis PD, McQuaker G, Parker A, Schey S et al. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 2002; 20: 4022\u20134031.","journal-title":"J Clin Oncol"},{"key":"BFbmt2009214_CR53","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/sj.bmt.1703606","volume":"30","author":"R Martino","year":"2002","unstructured":"Martino R, Caballero MD, de la Serna J, Diez-Martin JL, Urbano-Ispizua A, Tomas JF et al. Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant. Bone Marrow Transplant 2002; 30: 63\u201368.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2009214_CR54","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S1083-8791(03)00241-6","volume":"9","author":"HC Fung","year":"2003","unstructured":"Fung HC, Cohen S, Rodriguez R, Smith D, Krishnan A, Somlo G et al. Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed. Biol Blood Marrow Transplant 2003; 9: 649\u2013656.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2009214_CR55","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1053\/bbmt.2003.50014","volume":"9","author":"LC Feinstein","year":"2003","unstructured":"Feinstein LC, Sandmaier BM, Maloney DG, Maris MB, Gooley TA, Chauncey TR et al. Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant. Biol Blood Marrow Transplant 2003; 9: 266\u2013272.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2009214_CR56","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S0188-4409(03)00005-5","volume":"34","author":"GJ Ruiz-Arguelles","year":"2003","unstructured":"Ruiz-Arguelles GJ, Lopez-Martinez B, Lopez-Ariza B . Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed Hodgkin's disease following autologous stem cell transplantation. Arch Med Res 2003; 34: 242\u2013245.","journal-title":"Arch Med Res"},{"key":"BFbmt2009214_CR57","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1200\/JCO.2004.09.092","volume":"22","author":"MP Escalon","year":"2004","unstructured":"Escalon MP, Champlin RE, Saliba RM, Acholonu SA, Hosing C, Fayad L et al. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 2004; 22: 2419\u20132423.","journal-title":"J Clin Oncol"},{"key":"BFbmt2009214_CR58","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/sj.bmt.1704942","volume":"35","author":"P Anderlini","year":"2005","unstructured":"Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 2005; 35: 943\u2013951.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2009214_CR59","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1200\/JCO.2006.06.9914","volume":"24","author":"F Baron","year":"2006","unstructured":"Baron F, Storb R, Storer BE, Maris MB, Niederwieser D, Shizuru JA et al. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol 2006; 24: 4150\u20134157.","journal-title":"J Clin Oncol"},{"key":"BFbmt2009214_CR60","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/sj.bmt.1705977","volume":"41","author":"KJ Thomson","year":"2008","unstructured":"Thomson KJ, Peggs KS, Smith P, Cavet J, Hunter A, Parker A et al. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant 2008; 41: 765\u2013770.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2009214_CR61","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1365-2141.2008.07365.x","volume":"143","author":"AR Rezvani","year":"2008","unstructured":"Rezvani AR, Norasetthada L, Gooley T, Sorror M, Bouvier ME, Sahebi F et al. Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. Br J Haematol 2008; 143: 395\u2013403.","journal-title":"Br J Haematol"},{"key":"BFbmt2009214_CR62","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1182\/blood.V112.11.459.459","volume":"112","author":"CO Freytes","year":"2008","unstructured":"Freytes CO, Carreras J, Zhang MJ, Lapport G, van Besien K, Lazarus HM et al. Non-myeloablative allogeneic hematopoietic stem cell transplantation (NMHCT) for patients relapsing after autologous stem cell transplantation (autoHCT) for B cell Non-Hodgkin's lymphoma (NHL). Blood 2008; 112: 175 (abstract 459).","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2009214.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2009214","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2009214.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T12:30:34Z","timestamp":1648038634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2009214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,24]]},"references-count":62,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["BFbmt2009214"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2009.214","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,24]]},"assertion":[{"value":"10 July 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}